Marshall Edwards, Inc. CONTACTS: Warren Lancaster 203-966-2556 warren.lancaster@marshalledwardsinc.com David Sheon 202-547-2880 dsheon@WHITECOATstrategies.com MARSHALL EDWARDS ANNOUNCES ADDITIONAL MANAGEMENT CHANGES WITH

MARSHALL EDWARDS ANNOUNCES ADDITIONAL MANAGEMENT CHANGES WITH APPOINTMENT OF NEW CHIEF FINANCIAL

San Diego, CA June 17, 2010 Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology

company focused on the clinical development of novel anti-cancer therapeutics, announced today the

appointment of industry veteran Thomas Zech as Chief Financial Officer, less than two months after

appointing Daniel P. Gold, Ph.D., as the Company s new Chief Executive Officer.

Mr. Zech joins Marshall Edwards with more than 35 years of experience in finance and accounting,

including over 20 years in the life science industry. He replaces departing Chief Financial Officer

David Seaton, who also served as acting Chief Executive Officer from December 2009 until the

appointment of Dr. Gold in April 2010.

Tom is a welcome addition to our team, bringing a wealth of financial and management experience at

a critical stage in the evolution of Marshall Edwards. He will play a key role in the execution of

our transition to a fully operational U.S.-based company, said Dr. Gold. I would also like to

take this opportunity to thank David for his many contributions and for his stewardship and support

during this transition.

Mr. Zech served most recently as Vice President, Finance and Chief Financial Officer at Pacira

Pharmaceuticals, a specialty pharmaceutical company founded in 2007 through the acquisition of the

former SkyePharma PLC (NASDAQ: SKYE; LSE:SKP) injectable business. He transitioned to Pacira

Pharmaceuticals from SkyePharma Inc., where he joined in 1999 as Controller and Corporate

Secretary. Previously he held senior finance positions at Stratagene, Advanced Tissue Sciences,

Allied Holdings and Psicor. Mr. Zech earned his bachelor s degree in accounting from Lawrence

Technological University and his master s degree in finance from the University of Detroit.

About Marshall Edwards, Inc.

Marshall Edwards, Inc. (NASDAQ: MSHL) is a San Diego-based specialist oncology company focused on

the clinical development of novel anti-cancer therapeutics. These derive from an investigational

isoflavone technology platform, which has generated a number of novel compounds characterized by

broad ranging activity against a range of cancer cell types with few side effects. The combination

of anti-tumor cell activity and low toxicity is believed to be a result of the ability of these

compounds to target an enzyme present in the cell membrane of cancer cells, thereby inhibiting the

production of pro-survival proteins within the cell. Marshall Edwards has licensed rights from

Novogen Limited (ASX: NRT; NASDAQ: NVGN) to bring oncology drug candidates Phenoxodiol, Triphendiol

and NV-128 to market globally.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials

and approved by the FDA as being safe and effective for the intended use. Statements included in

this press release that are not historical in nature are forward-looking statements within the

meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

You should be aware that our actual results could differ materially from those contained in the

forward-looking statements, which are based on management s current expectations and are subject to

a number of risks and uncertainties, including, but not limited to, our failure to successfully

commercialize our product candidates; costs and delays in the development and/or FDA approval, or

the failure to obtain such approval, of our product candidates; uncertainties or differences in

interpretation in clinical trial results; our inability to maintain or enter into, and the risks

resulting from our dependence upon, collaboration or contractual arrangements necessary for the

development, manufacture, commercialization, marketing, sales and distribution of any products;

competitive factors; our inability to protect our patents or proprietary rights and obtain

necessary rights to third party patents and intellectual property to operate our business; our

inability to operate our business without infringing the patents and proprietary rights of others;

general economic conditions; the failure of any products to gain market acceptance; our inability

to obtain any additional required financing; technological changes; government regulation; changes

in industry practice; and one-time events. We do not intend to update any of these factors or to

publicly announce the results of any revisions to these forward-looking statements.